spacer
home > ebr > spring 2002 > a new technology for biopharmaceutical analyses - microfluidic-based lab-on-a-chip
PUBLICATIONS
European Biopharmaceutical Review

A New Technology for Biopharmaceutical Analyses - Microfluidic-Based Lab-on-a-Chip

Although the term 'lab-on-a-chip' is relatively new, the concept of applying chip technology to miniaturise analytical instruments is not. Its roots can be traced back to 1975 when the first attempts were made to use chip technology to miniaturise analytical instruments such as gas chromatographs. Technical problems prevented commercial success of the initial attempts. In recent years, however, the development of the new field of microfluidics has established itself as an important research area and is starting to appear in commercial products. There is great interest within the pharmaceutical industry in lab-on-a-chip devices because they promise to speed up the discovery process by allowing researchers to perform more analyses faster, more accurately and reproducibly whilst using much smaller sample volumes than is possible with conventional technology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Owen, Marketing Manager at Agilent Technologies, Germany

Dr Anthony Owen holds a degree in Chemistry and a doctorate in Physical Organic Chemistry from the University of Manchester Institute of Science and Technology. He briefly worked as a Research Chemist for Associated Octel in Ellesmere Port, UK, before joining Agilent Technologies (formerly Hewlett-Packard) in Vienna, Austria in 1979.
Since 1984 Anthony has been based in Waldbronn, Germany - firstly as Product Manager for UV-Visible spectroscopy, and since 2001 as Marketing Manager for the lab-on-a-chip products.

spacer
Dr Anthony Owen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement